Internal Medicine · Kalamazoo, MI
NPI
1326074378
Since 2006
Specialty
Internal Medicine
Code 207R00000X
Group practices
3
Medicare group memberships
Hospitals
6
Hospital affiliations
1717 Shaffer St, Ste 229
Kalamazoo, MI, 49048
Phone (269) 226-8321
Groups this clinician bills Medicare through
Medicare paid, 2024
$62K
1,091 services
Medicare patients, 2024
337
Average age 72
Drug cost, 2024
$9.3M
12,181 prescriptions
Company payments, 2025
$309K
From 19 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Michael Valitutto was code 99214 (office e&m - established), 612 times for 310 patients. In total Michael Valitutto billed 1,091 services in 13 codes, and Medicare paid $62K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-07-08.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 612 | 310 | $67.32 | $41K |
| 95251 Test - Miscellaneous | Office | 340 | 149 | $24.36 | $8,282 |
| 99215 Office E&M - Established | Office | 76 | 61 | $105.81 | $8,042 |
| 99204 Office E&M - New | Office | 38 | 38 | $85.66 | $3,255 |
By year: 2022 $62K for 1,074 services; 2023 $62K for 1,101 services; 2024 $62K for 1,091 services.
Lab tests billed to Medicare, 2022
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 82962 Clinical Chemistry | 21 | 13 | $1.46 | $30.69 |
Medicare prescription drug claims, 2024
In 2024, the drug Michael Valitutto prescribed most often to Medicare patients was Ozempic (Semaglutide), with 902 prescriptions and refills. In total Michael Valitutto wrote 12,181 Medicare prescriptions that cost $9.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ozempic Semaglutide | 902 | 1,452 | 203 | $1.4M |
| Jardiance Empagliflozin | 673 | 1,298 | 171 | $726K |
| Metformin Hcl Generic | 609 | 1,633 | 196 | $9,024 |
| Levothyroxine Sodium Generic | 554 | 1,252 | 149 | $7,572 |
| Atorvastatin Calcium Generic | 521 | 1,447 | 168 | $8,148 |
| Trulicity Dulaglutide | 504 | 738 | 115 | $696K |
| Mounjaro Tirzepatide | 444 | 618 | 92 | $630K |
| Farxiga Dapagliflozin Propanediol | 353 | 641 | 76 | $341K |
| Pioglitazone Hcl Generic | 321 | 838 | 86 | $8,625 |
| Novolog Insulin Aspart | 289 | 633 | 91 | $115K |
| Humalog Insulin Lispro | 275 | 567 | 83 | $83K |
| Metformin Hcl Er Metformin Hcl | 273 | 680 | 84 | $4,403 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 | 251 | 449 | 57 | $396K |
| Lisinopril Generic | 238 | 663 | 75 | $1,954 |
| Lantus Solostar Insulin Glargine,hum.Rec.Anlog | 206 | 527 | 88 | $49K |
Brand drugs: 5,844 claims; generic drugs: 5,045 claims; opioid claims: 51.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Michael Valitutto $309K ($309K in general payments such as food, travel and fees) from 19 companies. The largest payer was Novo Nordisk Inc with $83K.
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc NVO | 89 | $83K |
| Corcept Therapeutics CORT | 101 | $76K |
| Lilly USA, LLC LLY | 67 | $44K |
| Insulet Corporation PODD | 79 | $42K |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 41 | $29K |
| CeQur Corporation | 3 | $12K |
| Amgen Inc. AMGN | 30 | $8,205 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 23 | $7,375 |
| Abbott Laboratories ABT | 23 | $4,500 |
| Dexcom, Inc. DXCM | 18 | $3,799 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.